Racial/ethnic disparities in genomic sequencing

JAMA Oncology

Volumn 2, Issue 8, 2016, Pages 1070-1074

  Spratt, Daniel E ^a   Chan, Tiffany ^b   Waldron, Levi ^b   Speers, Corey ^a   Feng, Felix Y ^a   Ogunwobi, Olorunseun ^b   Osborne, Joseph R ^c,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; ALASKA NATIVE; ANCESTRY GROUP; ASIAN AMERICAN; CAUCASIAN; ETHNIC GROUP; ETHNOLOGY; GENETIC DATABASE; GENETICS; GENOMICS; HEALTH CARE DISPARITY; HISPANIC; HUMAN; MINORITY GROUP; MUTATION RATE; NEOPLASM; OCEANIC ANCESTRY GROUP; RETROSPECTIVE STUDY; UNITED STATES;

AFRICAN AMERICANS; ALASKA NATIVES; ASIAN AMERICANS; CONTINENTAL POPULATION GROUPS; DATABASES, GENETIC; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOMICS; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; MINORITY GROUPS; MUTATION RATE; NEOPLASMS; OCEANIC ANCESTRY GROUP; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85013689862     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.1854     Document Type: Article

References (10)

1. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006;24(14):2158-2163.
2. Shi Y, Au JS-K, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2): 154-162.
3. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484): 495-501.
4. Ateeq B, Bhatia V, Goel S. Molecular discriminators of racial disparities in prostate cancer. Trends in Cancer. 2016:2(3);116-119. doi:10 .1016/j.trecan.2016.01.005.
5. Spratt DE, Osborne JR. Disparities in castration-resistant prostate cancer trials. J Clin Oncol. 2015;33(10):1101-1103.
6. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366(9496):1527-1537.
7. Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
8. El-Telbany A, Ma PC. Cancer genes in lung cancer: racial disparities: Are there any? Genes Cancer. 2012;3(7-8):467-480.
9. Keenan T, Moy B, Mroz EA, et al. Comparison of the genomic landscape between primary breast cancer in African American vs white women and the association of racial differences with tumor recurrence. J Clin Oncol. 2015;33(31):3621-3627.
10. Yamoah K, Johnson MH, Choeurng V, et al. Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer. J Clin Oncol. 2015;33(25):2789-2796.